Vical Inc. has licensed its Vaxfectin technology, which is designed to make vaccines more effective, to a company that intends to use it in malaria vaccines.

Vical said privately held Cyvax is licensing Vaxfectin. The companies did not disclose financial terms of the agreement.

Vical also announced a licensing agreement with drugmaker Bristol-Myers Squibb Co. in September.

Release Date: December 5, 2012
Source: The Associated Press